Dihexa
Neurotrophic
Also known as: PNB-0408, N-hexanoic-Tyr-Ile-(6)aminohexanoic amide, N-hexanoyl-Tyr-Ile-6-aminohexanoamide
Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
From the primary source (McCoy/Benoist et al., J Pharmacol Exp Ther, PMC3533412): in RATS the serum half-life was ~12.68 days IV (~304 h) and ~8.83 days IP (~212 h); in-vitro liver-microsomal half-life 509.4 min with intrinsic clearance 2.72 uL/min/mg. These are striking values from a SINGLE Washington State University lab lineage and have not been independently replicated; human PK is unknown. Route matters: figures are IV/IP in rat, not oral or intranasal.
Model a dosing schedule →Preclinical only; rodent studies dose by mg/kg. No validated human dose. Do not translate animal mg/kg to human mcg.
Potent HGF/c-Met-potentiating neurotrophic activity reported in rodent AD models by the Harding/Benoist group (WSU). Impressive but single-lineage preclinical data; no human efficacy/safety data for Dihexa itself.
Lyophilised: General peptidomimetic convention: -20 C (no compound-specific data).
Reconstituted: General convention: 2-8 C (no compound-specific data).
No human safety data. Very long circulating half-life in rats means any adverse effect could be prolonged. Potent growth-factor pathway agonism raises theoretical proliferative concerns. Preclinical only.